Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
1(13%)
Results Posted
100%(4 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
2
25%
Ph not_applicable
3
38%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
2(28.6%)
N/ANon-phased studies
3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2
Enrolling by invitation1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (28.6%)
Phase 22 (28.6%)
N/A3 (42.9%)

Trials by Status

enrolling_by_invitation113%
completed450%
terminated225%
recruiting113%

Recent Activity

1 active trials
Showing 5 of 8
recruitingphase_1

PK and PD Study of NPI-001 and Cysteamine Bitartrate

NCT05994534
completednot_applicable

A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications

NCT02012114
terminatedphase_2

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

NCT02473445
completedphase_2

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease

NCT02023866
enrolling_by_invitation

Observational Study to Assess the Quality of Life in Nephropathic Cystinosis Patients

NCT04246060
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05994534Phase 1

PK and PD Study of NPI-001 and Cysteamine Bitartrate

Recruiting
NCT02012114Not Applicable

A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications

Completed
NCT02473445Phase 2

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Terminated
NCT02023866Phase 2

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease

Completed
NCT04246060

Observational Study to Assess the Quality of Life in Nephropathic Cystinosis Patients

Enrolling By Invitation
NCT03883984Phase 1

Cysteamine for Asthma

Completed
NCT00715559Not Applicable

Cysteamine Therapy for Major Depressive Disorder

Terminated
NCT01432561Not Applicable

Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8